Sensus Healthcare, Inc. (NASDAQ:SRTS) is expected to report third quarter earnings results, after market close, on Thursday 5th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.13 per share.
Looking ahead, the full year loss are expected at $ 0.6 per share on the revenues of $ 8.74 million.
Previous Quarter Performance
Sensus Healthcare, Inc. reported loss for the second quarter of $ 0.16 per share, from the revenue of $ 1.18 million. The quarterly revenues decreased 84.22 percent compared with the same quarter last year. Wall street analysts are predicting, SRTS to report 2Q20 loss of $ 0.18 per share from revenue of $ 1.53 million. The bottom line results beat street analysts by $ 0.02 or 11.11 percent, at the same time, top line results fell short of analysts by $ 0.35 million or 22.88 percent.
Stock Performance
Shares of Sensus Healthcare, Inc. traded up $ 0.02 or 0.84 percent on Wednesday, reaching $ 2.40 with volume of 1.80 thousand shares. Sensus Healthcare, Inc. has traded high as $ 2.42 and has cracked $ 2.36 on the downward trend
The closing price of $ 2.40, representing a 35.23 % increase from the 52 week low of $ 1.76 and a 58.46 % decrease over the 52 week high of $ 5.73.
The company has a market capital of $ 39.61 million and is part of the Healthcare sector and Medical Devices industry.
Conference Call
Sensus Healthcare, Inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.sensushealthcare.com
Sensus Healthcare, Inc. manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
